Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design

Publication date: Available online 6 March 2019Source: Biochimica et Biophysica Acta (BBA) - Proteins and ProteomicsAuthor(s): Brian C. Monk, Alia A. Sagatova, Parham Hosseini, Yasmeen N. Ruma, Rajni K. Wilson, Mikhail V. KeniyaAbstractThe cytochrome P450 enzyme lanosterol 14α-demethylase (LDM) is the target of the azole antifungals used widely in medicine and agriculture as prophylaxis or treatments of infections or diseases caused by fungal pathogens. These drugs and agrochemicals contain an imidazole, triazole or tetrazole substituent, with one of the nitrogens in the azole ring coordinating as the sixth axial ligand to the LDM. Structural studies show that this membrane bound enzyme contains a relatively rigid ligand binding pocket comprised of a deeply buried heme-containing active site together with a substrate entry channel and putative product exit channel that reach to the membrane. Within the ligand binding pocket the azole antifungals have additional affinity determining interactions with hydrophobic side-chains, the polypeptide backbone and via water-mediated hydrogen bond networks. This review will describe the tools that can be used to identify and characterise the next generation of antifungals targeting LDM, with the goal of obtaining highly potent broad-spectrum fungicides that will be able to avoid target- and drug-efflux mediated antifungal resistance.Graphical abstract

Source: Biochimica et Biophysica Acta (BBA) Proteins and Proteomics - March 8, 2019 Category: Biochemistry Source Type: research